{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:06:06Z","timestamp":1790726766372,"version":"4.1.0"},"reference-count":126,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Histone deacetylase 6 (HDAC6) is a large multidomain protein that deacetylates lysine residues on cytoplasmic proteins, influencing numerous cellular processes. Both the catalytic and noncatalytic functions of HDAC6 have been implicated in cancer development and progression. Over a decade of research on catalytic domain inhibitors has shown that these drugs are well tolerated, exhibit anticancer activity, and can alleviate chemotherapy-induced peripheral neuropathies. However, their effectiveness in treating solid tumours remains uncertain. HDAC6 activity is regulated by protein\u2013protein interactions and post-translational modifications, which may allosterically influence its catalytic domains. As a result, effective inhibition of HDAC6 in cancer using small molecule inhibitors requires a more sophisticated understanding of its role within tumour cells, including whether its expression correlates with deacetylase activity. A comprehensive understanding of cancer-specific HDAC6 expression, functional activity, and activation states will be critical for refining the use of HDAC6 inhibitors in cancer therapy.<\/jats:p>","DOI":"10.3390\/ijms26031274","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T04:36:51Z","timestamp":1738557411000},"page":"1274","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Regulation of HDAC6 Catalytic Activity in Cancer: The Role of Post-Translational Modifications and Protein\u2013Protein Interactions"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3367-2850","authenticated-orcid":false,"given":"Leen","family":"Asaad","sequence":"first","affiliation":[{"name":"School of Pharmacy, Queen\u2019s University Belfast, Belfast BT7 1NN, UK"},{"name":"Department of Pharmacology and Biomedical Sciences, Faculty of Pharmacy and Medical Sciences, University of Petra, Amman 11196, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pepperrell","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Queen\u2019s University Belfast, Belfast BT7 1NN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"McErlean","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Queen\u2019s University Belfast, Belfast BT7 1NN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9206-2297","authenticated-orcid":false,"given":"Fiona","family":"Furlong","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Queen\u2019s University Belfast, Belfast BT7 1NN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/carcin\/bgp220","article-title":"Epigenetics in cancer","volume":"31","author":"Sharma","year":"2010","journal-title":"Carcinogenesis"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Milazzo, G., Mercatelli, D., Di Muzio, G., Triboli, L., De Rosa, P., Perini, G., and Giorgi, F.M. (2020). Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability. Genes, 11.","DOI":"10.3390\/genes11050556"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/417455a","article-title":"HDAC6 is a microtubule-associated deacetylase","volume":"417","author":"Hubbert","year":"2002","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nchembio.2134","article-title":"Histone deacetylase 6 structure and molecular basis of catalysis and inhibition","volume":"12","author":"Hai","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1007\/s00018-015-2000-5","article-title":"Tubulin acetylation: Responsible enzymes, biological functions and human diseases","volume":"72","author":"Li","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.molcel.2005.04.021","article-title":"HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor","volume":"18","author":"Kovacs","year":"2005","journal-title":"Mol. Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.tcb.2008.04.003","article-title":"HDAC6: A key regulator of cytoskeleton, cell migration and cell\u2013cell interactions","volume":"18","author":"Cabrero","year":"2008","journal-title":"Trends Cell Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.molcel.2007.05.033","article-title":"HDAC6 modulates cell motility by altering the acetylation level of cortactin","volume":"27","author":"Zhang","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Zhu, Y., Feng, M., Wang, B., Zheng, Y., Jiang, D., Zhao, L., Mamun, M.A.A., Kang, H., Nie, H., and Zhang, X. (2023). New insights into the non-enzymatic function of HDAC6. Biomed. Pharmacother., 161.","DOI":"10.1016\/j.biopha.2023.114438"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1101\/gad.436407","article-title":"HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates","volume":"21","author":"Boyault","year":"2007","journal-title":"Genes Dev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2011.02.017","article-title":"HDAC6 \u03b1-tubulin deacetylase: A potential therapeutic target in neurodegenerative diseases","volume":"304","author":"Li","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s13238-014-0102-8","article-title":"Proteomic identification and functional characterization of MYH9, Hsc70, and DNAJA1 as novel substrates of HDAC6 deacetylase activity","volume":"6","author":"Zhang","year":"2015","journal-title":"Protein Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"11219","DOI":"10.1074\/jbc.M109.042754","article-title":"The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation","volume":"285","author":"Gao","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/febs.12079","article-title":"Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes","volume":"280","author":"Li","year":"2013","journal-title":"FEBS J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1074\/jbc.C500241200","article-title":"Two catalytic domains are required for protein deacetylation","volume":"281","author":"Zhang","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1093\/emboj\/cdf682","article-title":"In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation","volume":"21","author":"Matsuyama","year":"2002","journal-title":"EMBO J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors","volume":"280","author":"Bali","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/glia.22624","article-title":"HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes","volume":"62","author":"Noack","year":"2014","journal-title":"Glia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.bbadis.2018.11.014","article-title":"Acetylation as a major determinant to microtubule-dependent autophagy: Relevance to Alzheimer\u2019s and Parkinson disease pathology","volume":"1865","author":"Esteves","year":"2019","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Basis Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1021\/acs.biochem.0c00585","article-title":"HDAC6 ZnF UBP as the modifier of Tau structure and function","volume":"59","author":"Balmik","year":"2020","journal-title":"Biochemistry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1593\/neo.11558","article-title":"HDAC6 deacetylates Ku70 and regulates Ku70-Bax binding in neuroblastoma","volume":"13","author":"Subramanian","year":"2011","journal-title":"Neoplasia"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Boucherat, O., Chabot, S., Paulin, R., Trinh, I., Bourgeois, A., Potus, F., Lampron, M.-C., Lambert, C., Breuils-Bonnet, S., and Nadeau, V. (2017). HDAC6: A novel histone deacetylase implicated in pulmonary arterial hypertension. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-04874-4"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"10885","DOI":"10.1074\/jbc.M111.308791","article-title":"Histone deacetylase 6 (HDAC6) deacetylates survivin for its nuclear export in breast cancer","volume":"287","author":"Riolo","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9494052","DOI":"10.1155\/2018\/9494052","article-title":"Inhibition of HDAC6 activity alleviates myocardial ischemia\/reperfusion injury in diabetic rats: Potential role of peroxiredoxin 1 acetylation and redox regulation","volume":"2018","author":"Leng","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1073\/pnas.0803749105","article-title":"HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation","volume":"105","author":"Parmigiani","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"12686","DOI":"10.1074\/jbc.C700185200","article-title":"HDAC6 is required for epidermal growth factor-induced \u03b2-catenin nuclear localization","volume":"283","author":"Li","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1021\/acschembio.1c00303","article-title":"HDAC6 Substrate Discovery Using Proteomics-Based Substrate Trapping: HDAC6 Deacetylates PRMT5 to Influence Methyltransferase Activity","volume":"16","author":"Gomes","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1158\/1078-0432.CCR-08-0642","article-title":"Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor","volume":"14","author":"Bazzaro","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ali, A., Zhang, F., Maguire, A., Byrne, T., Weiner-Gorzel, K., Bridgett, S., O\u2019toole, S., O\u2019leary, J., Beggan, C., and Fitzpatrick, P. (2020). HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells. Cancers, 12.","DOI":"10.3390\/cancers12123734"},{"key":"ref_30","first-page":"117","article-title":"Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma","volume":"29","author":"Sakuma","year":"2006","journal-title":"Int. J. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3892\/or.2012.1898","article-title":"Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells","volume":"28","author":"Kanno","year":"2012","journal-title":"Oncol. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/sj.leu.2403910","article-title":"Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors","volume":"19","author":"Bradbury","year":"2005","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Aldana-Masangkay, G.I., and Sakamoto, K.M. (2010). The role of HDAC6 in cancer. J. Biomed. Biotechnol., 2011.","DOI":"10.1155\/2011\/875824"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6962","DOI":"10.1158\/1078-0432.CCR-04-0455","article-title":"HDAC6 expression is correlated with better survival in breast cancer","volume":"10","author":"Zhang","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1038\/sj.onc.1208646","article-title":"Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer","volume":"24","author":"Saji","year":"2005","journal-title":"Oncogene"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1096\/fj.11-191742","article-title":"Phthalates induce proliferation and invasiveness of estrogen receptor-negative breast cancer through the AhR\/HDAC6\/c-Myc signaling pathway","volume":"26","author":"Hsieh","year":"2012","journal-title":"FASEB J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"742","DOI":"10.4161\/cbt.28469","article-title":"Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells","volume":"15","author":"Rosik","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41419-018-0788-2","article-title":"Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d\/PI3K\/AKT\/mTOR and ERK pathways","volume":"9","author":"Cao","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1002\/jcb.26841","article-title":"Retracted: Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90","volume":"119","author":"Tao","year":"2018","journal-title":"J. Cell Biochem."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Zhou, B., Liu, D., and Tan, Y. (2021). Role of HDAC6 and its selective inhibitors in gastrointestinal cancer. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.719390"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s13238-013-0010-3","article-title":"Histone deacetylase 6 and cytoplasmic linker protein 170 function together to regulate the motility of pancreatic cancer cells","volume":"5","author":"Li","year":"2014","journal-title":"Protein Cell"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Wang, G., He, J., Zhao, J., Yun, W., Xie, C., Taub, J.W., Azmi, A., Mohammad, R.M., Dong, Y., and Kong, W. (2012). Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0052095"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1615\/CritRevEukaryotGeneExpr.2023049102","article-title":"Comprehensive Characterization of HATs and HDACs in Human Cancers Reveals Their Role in Immune Checkpoint Blockade","volume":"34","author":"Sun","year":"2024","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13058-015-0658-0","article-title":"HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers","volume":"17","author":"Putcha","year":"2015","journal-title":"Breast Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S12.1","DOI":"10.1186\/gb-2006-7-12-121","article-title":"AceView: A comprehensive cDNA-supported gene and transcripts annotation","volume":"7","year":"2006","journal-title":"Genome Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.bbrc.2010.01.091","article-title":"Requirement of a novel splicing variant of human histone deacetylase 6 for TGF-\u03b21-mediated gene activation","volume":"392","author":"Zhuang","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Foschini, M.P., Morandi, L., Sanchez, A.M., Santoro, A., Mule, A., Zannoni, G.F., Varga, Z., Moskovszky, L., Cucchi, M.C., and Moelans, C.B. (2020). Methylation Profile of X-Chromosome-Related Genes in Male Breast Cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00784"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s13402-022-00704-6","article-title":"HDAC6: A unique HDAC family member as a cancer target","volume":"45","author":"Kaur","year":"2022","journal-title":"Cell. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/mc.22345","article-title":"Downregulation of HDAC6 promotes angiogenesis in hepatocellular carcinoma cells and predicts poor prognosis in liver transplantation patients","volume":"55","author":"Lv","year":"2016","journal-title":"Mol. Carcinog."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"495","DOI":"10.4161\/cam.21585","article-title":"The interplay between G protein-coupled receptor kinase 2 (GRK2) and histone deacetylase 6 (HDAC6) at the crossroads of epithelial cell motility","volume":"6","author":"Lafarga","year":"2012","journal-title":"Cell Adhes. Migr."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/emboj.2011.466","article-title":"A novel GRK2\/HDAC6 interaction modulates cell spreading and motility","volume":"31","author":"Lafarga","year":"2012","journal-title":"EMBO J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0092-8674(03)00939-5","article-title":"The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress","volume":"115","author":"Kawaguchi","year":"2003","journal-title":"Cell"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Fusco, C., Micale, L., Egorov, M., Monti, M., D\u2019Addetta, E.V., Augello, B., Cozzolino, F., Calcagni, A., Fontana, A., and Polishchuk, R.S. (2012). The E3-ubiquitin ligase TRIM50 interacts with HDAC6 and p62, and promotes the sequestration and clearance of ubiquitinated proteins into the aggresome. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0040440"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.bbamcr.2019.03.003","article-title":"Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo","volume":"1866","author":"Hsieh","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1042\/CS20160084","article-title":"The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease","volume":"130","author":"Batchu","year":"2016","journal-title":"Clin. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/emboj.2009.317","article-title":"CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin","volume":"29","author":"Masoumi","year":"2010","journal-title":"EMBO J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.febslet.2013.02.001","article-title":"HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity","volume":"587","author":"Ding","year":"2013","journal-title":"FEBS Lett."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3892\/or.2021.8252","article-title":"Inhibition of triple-negative breast cancer proliferation and motility by reactivating p53 and inhibiting overactivated Akt","volume":"47","author":"Cao","year":"2022","journal-title":"Oncol. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/s41416-018-0232-5","article-title":"The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death","volume":"119","author":"Kaliszczak","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/emboj.2009.405","article-title":"HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy","volume":"29","author":"Lee","year":"2010","journal-title":"EMBO J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature05853","article-title":"HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS","volume":"447","author":"Pandey","year":"2007","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1158\/0008-5472.CAN-08-0188","article-title":"The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis","volume":"68","author":"Lee","year":"2008","journal-title":"Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/jclinpath-2012-200940","article-title":"Cortactin is associated with tumour progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ","volume":"65","author":"Hou","year":"2012","journal-title":"J. Clin. Pathol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1128\/MCB.26.1.28-38.2006","article-title":"Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage","volume":"26","author":"Solomon","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.canlet.2017.12.005","article-title":"HDAC6 inhibition induces glioma stem cells differentiation and enhances cellular radiation sensitivity through the SHH\/Gli1 signaling pathway","volume":"415","author":"Yang","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6731","DOI":"10.21873\/anticanres.13888","article-title":"Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair","volume":"39","author":"Kim","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Anraku, T., Murata, M., Kuroki, H., Kazama, A., Shirono, Y., Tasaki, M., Bilim, V., and Tomita, Y. (2024). Selective HDAC6 Inhibition Has the Potential for Anti-Cancer Effect in Renal Cell Carcinoma. J. Pers. Med., 14.","DOI":"10.3390\/jpm14070704"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/jop.13326","article-title":"Pharmacological inhibition of HDAC6 overcomes cisplatin chemoresistance by targeting cancer stem cells in oral squamous cell carcinoma","volume":"51","author":"Tavares","year":"2022","journal-title":"J. Oral. Pathol. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/pros.24678","article-title":"A novel HDAC6 inhibitor interferes microtubule dynamics and spindle assembly checkpoint and sensitizes cisplatin-induced apoptosis in castration-resistant prostate cancer","volume":"84","author":"Ye","year":"2024","journal-title":"Prostate"},{"key":"ref_70","first-page":"2579","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"eabc4897","DOI":"10.1126\/sciadv.abc4897","article-title":"Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer","volume":"7","author":"Dowling","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.4049\/jimmunol.1302778","article-title":"A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3\/IL-10 pathway in APCs","volume":"193","author":"Cheng","year":"2014","journal-title":"J. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.molonc.2015.12.012","article-title":"Essential role of HDAC6 in the regulation of PD-L1 in melanoma","volume":"10","author":"Lienlaf","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00280-018-3721-6","article-title":"Role of the HDAC6\/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines","volume":"83","author":"Keremu","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms Controlling PD-L1 Expression in Cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.semcdb.2022.09.009","article-title":"Immunomodulatory properties of HDAC6 inhibitors in cancer diseases: New chances for sophisticated drug design and treatment optimization","volume":"154","author":"Biersack","year":"2024","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"13162","DOI":"10.1073\/pnas.1608067113","article-title":"Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma","volume":"113","author":"Hideshima","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1182\/blood.V128.22.3307.3307","article-title":"Selective HDAC6 inhibitor ACY-241, an oral tablet, combined with pomalidomide and dexamethasone: Safety and efficacy of escalation and expansion cohorts in patients with relapsed or relapsed-and-refractory multiple myeloma (ACE-MM-200 Study)","volume":"128","author":"Niesvizky","year":"2016","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S1470-2045(16)30375-8","article-title":"Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A multicentre phase 1b trial","volume":"17","author":"Yee","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1182\/blood.V120.21.4061.4061","article-title":"Rocilinostat (ACY-1215), a selective HDAC6 inhibitor, alone and in combination with bortezomib in multiple myeloma: Preliminary results from the first-in-humans phase I\/II study","volume":"120","author":"Raje","year":"2012","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"184-e366","DOI":"10.1002\/onco.13673","article-title":"First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma","volume":"26","author":"Amengual","year":"2021","journal-title":"Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1158\/1078-0432.CCR-14-3068","article-title":"Dual targeting of protein degradation pathways with the selective HDAC6 inhibitor ACY-1215 and bortezomib is synergistic in lymphoma","volume":"21","author":"Amengual","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/j.pain.0000000000000893","article-title":"HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy","volume":"158","author":"Krukowski","year":"2017","journal-title":"Pain"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.gore.2019.07.010","article-title":"Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer","volume":"29","author":"Lee","year":"2019","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1200\/JCO.2018.36.15_suppl.1058","article-title":"Phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in metastatic breast cancer","volume":"36","author":"Kalinsky","year":"2018","journal-title":"Am. Soc. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Awad, M.M., Le Bruchec, Y., Lu, B., Ye, J., Miller, J., Lizotte, P.H., Cavanaugh, M.E., Rode, A.J., Dumitru, C.D., and Spira, A. (2021). Selective histone deacetylase inhibitor ACY-241 (citarinostat) plus nivolumab in advanced Non-Small cell lung cancer: Results from a phase ib study. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.696512"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Huang, Z., Li, L., Cheng, B., and Li, D. (2024). Small molecules targeting HDAC6 for cancer treatment: Current progress and novel strategies. Biomed. Pharmacother., 178.","DOI":"10.1016\/j.biopha.2024.117218"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"CT151","DOI":"10.1158\/1538-7445.AM2020-CT151","article-title":"Abstract CT151: Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors","volume":"80","author":"Tsimberidou","year":"2020","journal-title":"Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Gordon, M.S., Shapiro, G.I., Sarantopoulos, J., Juric, D., Lu, B., Zarotiadou, A., Connarn, J.N., Le Bruchec, Y., Dumitru, C.D., and Harvey, R.D. (2022). Phase Ib study of the histone deacetylase 6 inhibitor citarinostat in combination with paclitaxel in patients with advanced solid tumors. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.786120"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Li, J., Yu, M., Fu, S., Liu, D., and Tan, Y. (2022). Role of selective histone deacetylase 6 inhibitor ACY-1215 in cancer and other human diseases. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.907981"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Alothaim, T., Charbonneau, M., and Tang, X. (2021). HDAC6 inhibitors sensitize non-mesenchymal triple-negative breast cancer cells to cysteine deprivation. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-90527-6"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jtho.2023.03.014","article-title":"Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC","volume":"18","author":"Zhang","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ncb3582","article-title":"ARID1A-mutated ovarian cancers depend on HDAC6 activity","volume":"19","author":"Bitler","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.ejmech.2017.10.040","article-title":"Recent advances in the discovery of potent and selective HDAC6 inhibitors","volume":"143","author":"Wang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ijc.32169","article-title":"Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models","volume":"145","author":"Depetter","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"10339","DOI":"10.1021\/acs.jmedchem.9b01888","article-title":"Multicomponent Synthesis, Binding Mode, and Structure\u2013Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups","volume":"63","author":"Osko","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s43018-022-00489-5","article-title":"Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer","volume":"4","author":"Zeleke","year":"2023","journal-title":"Nat. Cancer"},{"key":"ref_98","first-page":"ra84","article-title":"Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6","volume":"2","author":"Deribe","year":"2009","journal-title":"Sci. Signal."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"33156","DOI":"10.1074\/jbc.M113.472506","article-title":"Extracellular signal-regulated kinase (ERK) phosphorylates histone deacetylase 6 (HDAC6) at serine 1035 to stimulate cell migration","volume":"288","author":"Williams","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1074\/jbc.M117.795955","article-title":"Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity","volume":"293","author":"Wu","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Chen, S., Owens, G.C., Makarenkova, H., and Edelman, D.B. (2010). HDAC6 regulates mitochondrial transport in hippocampal neurons. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010848"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Bahram Sangani, N., Koetsier, J., Melius, J., Kutmon, M., Ehrhart, F., Evelo, C.T., Curfs, L.M.G., Reutelingsperger, C.P., and Eijssen, L.M.T. (2024). A novel insight into neurological disorders through HDAC6 protein-protein interactions. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-65094-1"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"38879","DOI":"10.1074\/jbc.M505733200","article-title":"Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes","volume":"280","author":"Chen","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Du, Y., Seibenhener, M.L., Yan, J., Jiang, J., and Wooten, M.C. (2015). aPKC phosphorylation of HDAC6 results in increased deacetylation activity. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0123191"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pharmthera.2016.04.005","article-title":"Diverse roles of HDAC6 in viral infection: Implications for antiviral therapy","volume":"164","author":"Zhang","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1242\/jcs.081778","article-title":"Protein kinase CK2 regulates the formation and clearance of aggresomes in response to stress","volume":"124","author":"Watabe","year":"2011","journal-title":"J. Cell Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"29168","DOI":"10.1074\/jbc.M112.371120","article-title":"Modulation of histone deacetylase 6 (HDAC6) nuclear import and tubulin deacetylase activity through acetylation","volume":"287","author":"Liu","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bbrc.2009.03.147","article-title":"Acetylation of histone deacetylase 6 by p300 attenuates its deacetylase activity","volume":"383","author":"Han","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"17896","DOI":"10.1074\/jbc.M109.096578","article-title":"TPPP\/p25 promotes tubulin acetylation by inhibiting histone deacetylase 6","volume":"285","author":"Lehotzky","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Ol\u00e1h, J., Szunyogh, S., Szenasi, T., Szaniszl\u00f3, T., Szab\u00f3, A., Lehotzky, A., Berki, T., Nyitray, L., and Ov\u00e1di, J. (2019). Interactions between two regulatory proteins of microtubule dynamics, HDAC6, TPPP\/p25, and the hub protein, DYNLL\/LC8. Biochim. Biophys. Acta (BBA)-Mol. Cell Res., 1866.","DOI":"10.1016\/j.bbamcr.2019.118556"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Yan, J., Seibenhener, M.L., Calderilla-Barbosa, L., Diaz-Meco, M.-T., Moscat, J., Jiang, J., Wooten, M.W., and Wooten, M.C. (2013). SQSTM1\/p62 interacts with HDAC6 and regulates deacetylase activity. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0076016"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1083\/jcb.201001039","article-title":"Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy","volume":"189","author":"Lee","year":"2010","journal-title":"J. Cell Biol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1242\/jcs.02425","article-title":"A novel Rho-mDia2-HDAC6 pathway controls podosome patterning through microtubule acetylation in osteoclasts","volume":"118","author":"Destaing","year":"2005","journal-title":"J. Cell Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1091\/mbc.e17-08-0488","article-title":"Paxillin regulates cell polarization and anterograde vesicle trafficking during cell migration","volume":"28","author":"Dubois","year":"2017","journal-title":"Mol. Biol. Cell"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1083\/jcb.201403039","article-title":"Paxillin inhibits HDAC6 to regulate microtubule acetylation, Golgi structure, and polarized migration","volume":"206","author":"Deakin","year":"2014","journal-title":"J. Cell Biol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"13425","DOI":"10.1073\/pnas.172511699","article-title":"Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquitinating enzymes","volume":"99","author":"Hook","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.tibs.2008.05.005","article-title":"Zinc-finger UBPs: Regulators of deubiquitylation","volume":"33","author":"Bonnet","year":"2008","journal-title":"Trends Biochem. Sci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.molcel.2013.08.016","article-title":"Proteasomes activate aggresome disassembly and clearance by producing unanchored ubiquitin chains","volume":"51","author":"Hao","year":"2013","journal-title":"Mol. Cell"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"8035","DOI":"10.1128\/MCB.21.23.8035-8044.2001","article-title":"Identification of components of the murine histone deacetylase 6 complex: Link between acetylation and ubiquitination signaling pathways","volume":"21","author":"Verdel","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1038\/sj.emboj.7601210","article-title":"HDAC6-p97\/VCP controlled polyubiquitin chain turnover","volume":"25","author":"Boyault","year":"2006","journal-title":"EMBO J."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"10144","DOI":"10.1021\/acs.jmedchem.9b00988","article-title":"Discovery of Small Molecule Antagonists of the USP5 Zinc Finger Ubiquitin-Binding Domain","volume":"62","author":"Mann","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1021\/acs.jmedchem.8b00258","article-title":"Identification and Structure-Activity Relationship of HDAC6 Zinc-Finger Ubiquitin Binding Domain Inhibitors","volume":"61","author":"Harding","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"110736","DOI":"10.1016\/j.celrep.2022.110736","article-title":"Disrupting the HDAC6-ubiquitin interaction impairs infection by influenza and Zika virus and cellular stress pathways","volume":"39","author":"Wang","year":"2022","journal-title":"Cell Rep."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Ol\u00e1h, J., Lehotzky, A., Szunyogh, S., Sz\u00e9n\u00e1si, T., Orosz, F., and Ov\u00e1di, J. (2020). Microtubule-associated proteins with regulatory functions by day and pathological potency at night. Cells, 9.","DOI":"10.3390\/cells9020357"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Lemos, M., and Stefanova, N. (2020). Histone deacetylase 6 and the disease mechanisms of \u03b1-synucleinopathies. Front. Synaptic Neurosci., 12.","DOI":"10.3389\/fnsyn.2020.586453"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/3\/1274\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:25:31Z","timestamp":1760027131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/3\/1274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":126,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["ijms26031274"],"URL":"https:\/\/doi.org\/10.3390\/ijms26031274","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}